Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px
Organisation › Details

LegoChem Biosciences, Inc. (LCB) (KOSDAQ: 141080)

LegoChem Biosicences, Inc., established in May 2006 at Daedeok Innopolis, utilizes its unique LegoChemistry synthesis platform to develop novel antibiotic, anticoagulant, and anticancer drugs. They have also recently developed a novel antibody drug conjugate (ADC) platform technology to bring novel tools to solve targeted drug delivery system problems. In 1991, Dr. Yong Zu Kim developed a novel cephalosporin antibiotic that became Korea's first novel drug to be licensed out (to Glaxo Wellcome, now GlaxoSmithKline) while he was head of the research unit at LG Life Science. Dr. Kim is a leading antibiotic expert who played a major role in Korea's first FDA-approved drug "FACTIVE", also while he was at LG Life Science. In December of 2012, LegoChem successfully met the listing requirements of the Technology Assessment Exemption Program of the KOSDAQ, and is currently in the process of becoming a publicly traded company by early 2013. *


Period Start 2006-05-01 established
Products Industry antibody-drug conjugates (ADC) technology
  Industry 2 therapeutic antibody
Persons Person Kim, Yong-Zu (LegoChem Biosciences 202111 CEO)
  Person 2 Chae, Jeiwook (LegoChem 201610 Chief Business Development Officer)
  Street 461.8 Jeonim-dong
Daejeon Bio Venture Town, Yuseong-gu
  City 305-811 Daejeon
  Tel +82-42-861-0688
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: 
Record changed: 2021-12-05


Picture [iito] No Tracking 650x100px

More documents for LegoChem Biosciences, Inc. (LCB) (KOSDAQ: 141080)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top